Akebia Therapeutics (AKBA)
NASDAQ:AKBA
Want to see AKBA full AI Analyst Report?
Top Page
Akebia Therapeutics
(NASDAQ:AKBA)
Select Model
Select Model
Rating:54Neutral
Price Target:
$0.96
▼(-31.79% Downside)
Action:Reiterated
Date:06/03/26
AKBA scores in the mid-range primarily because financial performance is improving (strong positive operating/free cash flow and reduced leverage), but the technical trend is decisively bearish (below all key moving averages with negative MACD). Earnings call takeaways are mixed—Vafseo momentum and pipeline progress are positives, while Auryxia erosion, a swing to net loss, and cash decline temper the outlook; valuation is limited by a negative P/E and no dividend yield data.
Positive Factors
Cash generation / FCF
Sustained positive operating and free cash flow (~$60M TTM) marks a structural turnaround from prior years. This strengthens liquidity, funds R&D and commercialization without immediate dilution, and provides multi-quarter optionality to execute trials and market expansion.
Negative Factors
Auryxia generic erosion
Loss of pricing and share for Auryxia from authorized and new generics is a structural revenue headwind. Continued 2026 declines reduce diversification of revenue, increase reliance on Vafseo and pipeline outcomes, and pressure near-term cash and margin profiles.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash generation / FCF
Sustained positive operating and free cash flow (~$60M TTM) marks a structural turnaround from prior years. This strengthens liquidity, funds R&D and commercialization without immediate dilution, and provides multi-quarter optionality to execute trials and market expansion.
Read all positive factors
Akebia Therapeutics (AKBA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$260.13M
Dividend YieldN/A
Average Volume (3M)4.64M
Price to Earnings (P/E)―
Beta (1Y)0.96
Revenue Growth25.69%
EPS Growth64.06%
CountryUS
Employees181
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.08
Shares Outstanding268,258,240
10 Day Avg. Volume5,255,480
30 Day Avg. Volume4,644,124
Financial Highlights & Ratios
PEG Ratio0.83
Price to Book (P/B)12.70
Price to Sales (P/S)1.75
P/FCF Ratio6.09
Enterprise Value/Market Cap0.47
Enterprise Value/Revenue0.53
Enterprise Value/Gross Profit0.66
Enterprise Value/Ebitda39.04
Forecast
1Y Price Target
$4.67Price Target Upside233.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.11
Revenue Forecast (FY)$217.59M
Akebia Therapeutics Business Overview & Revenue Model
Company Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy...
How the Company Makes Money
Akebia makes money primarily through commercialization-related revenue from its kidney-disease products and through collaboration/partnering economics. Key revenue streams include: (1) Product sales: revenue from sales of Vafseo (vadadustat) in ma...
Akebia Therapeutics Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Neutral
The call highlights strong commercial momentum for Vafseo (32% revenue growth, ~60% patient growth quarter-over-quarter, higher prescriber engagement and improved adherence under observed dosing) and meaningful pipeline progress with supportive clinical data and upcoming readouts. However, legacy product Auryxia faces notable generic-driven revenue decline (≈-17%), the company swung to a net loss in the quarter, experienced sizable inventory write-downs and higher operating expenses, and cash declined q/q. While the launch and clinical developments are encouraging and provide a clear growth narrative, the near-term financial headwinds and competitive/enrollment risks temper the outlook.Positive Updates
Strong Vafseo Quarterly Revenue Growth
Vafseo net product revenues were $15.8M in Q1 2026 versus $12.0M in Q1 2025, a 32% year-over-year increase and the highest quarter of Vafseo revenue to date.
Negative Updates
Overall Revenue Decline
Total revenues were $53.5M in Q1 2026 versus $57.3M in Q1 2025, a decline of $3.8M or approximately -6.6% year-over-year, driven by lower Auryxia revenues despite higher Vafseo sales.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Vafseo Quarterly Revenue Growth
Vafseo net product revenues were $15.8M in Q1 2026 versus $12.0M in Q1 2025, a 32% year-over-year increase and the highest quarter of Vafseo revenue to date.
Read all positive updates
Company Guidance
Akebia’s call guided to continued commercial and pipeline execution: Q1’26 total revenues were $53.5M with Vafseo net product revenue of $15.8M (highest quarter-to-date; +32% YoY from $12.0M) and Auryxia $36.2M (down from $43.8M), license/collab revenues $1.6M; Vafseo patients grew to nearly 7,500 (≈60% QoQ), ~1,025 prescribers (+28% vs Q4’25) with ~30% from non‑USRC dialysis organizations, ~2/3 of patients on 3x/week dosing and first‑refill adherence ≈86% (85–90% range); cash was $162.6M (vs $184.8M 12/31/25) and expected to fund operations ≥2 years; company expects TDAPA opportunity for the balance of 2026 and bundle entry planning for 2027, anticipates Auryxia revenues to decline in 2026, and reiterated pipeline milestones—VOCAL topline by year‑end 2026, VOICE early 2027, AKB‑9090 Phase I (up to 70 participants) topline early 2027, praliciguat Phase II targeting ~60 patients, and AKB‑097 Phase II basket to start H2’26 with initial data in 2027.Akebia Therapeutics Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
48
Neutral
Cash Flow
72
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 232.40M | 236.20M | 160.18M | 194.62M | 292.48M | 211.65M |
| Gross Profit | 187.95M | 196.73M | 97.00M | 120.47M | 269.99M | 130.16M |
| EBITDA | 3.16M | 21.73M | -13.72M | -8.27M | 3.06M | -189.91M |
| Net Income | -20.51M | -5.34M | -69.41M | -51.92M | -94.23M | -282.02M |
Balance Sheet | ||||||
| Total Assets | 362.52M | 376.56M | 220.67M | 241.70M | 356.05M | 529.35M |
| Cash, Cash Equivalents and Short-Term Investments | 162.64M | 184.84M | 51.87M | 42.92M | 90.47M | 149.80M |
| Total Debt | 12.49M | 216.30M | 188.73M | 104.18M | 99.78M | 136.05M |
| Total Liabilities | 335.14M | 343.95M | 269.86M | 272.29M | 350.82M | 455.34M |
| Stockholders Equity | 27.38M | 32.61M | -49.19M | -30.58M | 5.23M | 74.01M |
Cash Flow | ||||||
| Free Cash Flow | 60.01M | 67.99M | -40.69M | -23.38M | -73.27M | -253.02M |
| Operating Cash Flow | 60.37M | 67.99M | -40.66M | -23.38M | -73.15M | -252.97M |
| Investing Cash Flow | -8.14M | -7.93M | -33.00K | 0.00 | -114.00K | 39.94M |
| Financing Cash Flow | -2.94M | 72.93M | 49.66M | -25.21M | 14.60M | 133.73M |
Akebia Therapeutics Technical Analysis
Negative
1.40
Price Trends
1.27
Negative
1.31
Negative
1.82
Negative
Market Momentum
-0.09
Negative
35.31
Neutral
31.64
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AKBA, the sentiment is Negative. The current price of 1.4 is above the 20-day moving average (MA) of 1.05, above the 50-day MA of 1.27, and below the 200-day MA of 1.82, indicating a bearish trend. The MACD of -0.09 indicates Negative momentum. The RSI at 35.31 is Neutral, neither overbought nor oversold. The STOCH value of 31.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AKBA.
Akebia Therapeutics Risk Analysis
Akebia Therapeutics disclosed 60 risk factors in its most recent earnings report. Akebia Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Akebia Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $820.72M | 7.33 | 43.85% | ― | 68.20% | ― | |
57 Neutral | $1.39B | -10.27 | -48.98% | ― | ― | 6.28% | |
54 Neutral | $260.13M | -12.63 | -62.72% | ― | 25.69% | 64.06% | |
52 Neutral | $1.48B | -3.05 | -53.31% | ― | 213.96% | 25.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $3.45B | -29.56 | -25.99% | ― | ― | 54.61% | |
44 Neutral | $522.56M | -3.51 | 7.40% | ― | 190.52% | 12.60% |
* Healthcare Sector Average
AKBA
Akebia Therapeutics
0.94
-3.04
-76.45%
ORKA
Oruka Therapeutics
60.14
47.56
378.06%
TBPH
Theravance Biopharma
16.29
5.04
44.80%
VIR
Vir Biotechnology
8.65
3.20
58.72%
PROK
ProKidney
1.80
0.82
83.67%
AVBP
ArriVent BioPharma, Inc.
30.35
6.83
29.04%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.